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Abstract
Background: Antiphospholipid antibodies (aPL) can be detected in asymptomatic carriers and infectious patients.
The aim was to investigate whether a novel line immunoassay (LIA) differentiates between antiphospholipid
syndrome (APS) and asymptomatic aPL+ carriers or patients with infectious diseases (infectious diseases controls (IDC)).
Methods: Sixty-one patients with APS (56 primary, 22/56 with obstetric events only, and 5 secondary), 146 controls
including 24 aPL+ asymptomatic carriers and 73 IDC were tested on a novel hydrophobic solid phase coated
with cardiolipin (CL), phosphatic acid, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol,
phosphatidylinositol, phosphatidylserine, beta2-glycoprotein I (β2GPI), prothrombin, and annexin V. Samples
were also tested by anti-CL and anti-β2GPI ELISAs and for lupus anticoagulant activity. Human monoclonal
antibodies (humoAbs) against human β2GPI or PL alone were tested on the same LIA substrates in the
absence or presence of human serum, purified human β2GPI or after CL-micelle absorption.
Results: Comparison of LIA with the aPL-classification assays revealed good agreement for IgG/IgM aß2GPI
and aCL. Anti-CL and anti-ß2GPI IgG/IgM reactivity assessed by LIA was significantly higher in patients with
APS versus healthy controls and IDCs, as detected by ELISA. IgG binding to CL and ß2GPI in the LIA was
significantly lower in aPL+ carriers and Venereal Disease Research Laboratory test (VDRL) + samples than in
patients with APS. HumoAb against domain 1 recognized β2GPI bound to the LIA-matrix and in anionic
phospholipid (PL) complexes. Absorption with CL micelles abolished the reactivity of a PL-specific humoAb
but did not affect the binding of anti-β2GPI humoAbs.
Conclusions: The LIA and ELISA have good agreement in detecting aPL in APS, but the LIA differentiates patients
with APS from infectious patients and asymptomatic carriers, likely through the exposure of domain 1.
Keywords: Antiphospholipid syndrome, Antiphospholipid antibody, Phospholipid binding proteins, Beta2 -
glycoprotein I, Line immunoassay
* Correspondence: dirk.roggenbuck@b-tu.de
†Equal contributors
1Institute of Biotechnology, Faculty 2, Brandenburg University of Technology
Cottbus-Senftenberg, Großenhainer Str. 57, 01968 Senftenberg, Germany
2Research and Development Department, Medipan GmbH, Dahlewitz/Berlin,
Germany
Full list of author information is available at the end of the article
© 2016 Roggenbuck et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Roggenbuck et al. Arthritis Research & Therapy  (2016) 18:111 
DOI 10.1186/s13075-016-1018-x
Background
Antiphospholipid syndrome (APS) represents a chronic
disabling systemic autoimmune disorder affecting ap-
proximately 1 % of the general population and occurring
as the primary disorder or being associated with other
systemic autoimmune rheumatic diseases. Clinical mani-
festations are represented by recurrent arterial/venous
thrombosis and/or pregnancy morbidity in the persistent
presence of antiphospholipid antibodies (aPL) [1–4].
The current international consensus for the classifi-
cation of APS values clinical and laboratory criteria
equally for the diagnosis of APS [2]. The latter criter-
ion comprises the detection of persistent aPL by
solid-phase assays, i.e., IgG and IgM to beta2 - glyco-
protein I (β2GPI) and the cardiolipin (CL)-β2GPI
complex, and by a functional clotting test, i.e., the
lupus anticoagulant (LA).
Appropriate aPL analysis, however, still remains a la-
boratory challenge due to the heterogeneity of aPL and
standardization issues for the required ELISA and clot-
ting tests [5–8]. Recent studies suggested that the
epitope specificity of anti-β2GPI antibodies may differ-
entiate between anti-domain (D)1 antibodies that are as-
sociated with the manifestations of the syndrome and
the anti-D4/5 antibodies, which are not [9]. Apart
from β2GPI, other phospholipid (PL)-binding proteins
such as prothrombin (PT), annexin V (AnV), and
high-molecular weight kininogen have been described
[10–12]. Furthermore, the relevance of aPL assay
techniques involving the interaction of PL-binding
proteins like β2GPI and PT with PLs other than CL, such
as phosphatidylserine (PS), is still a matter of debate and
not yet included in the classification criteria [13].
For risk stratification in patients with APS, different
profiles comprising single, double, and triple positivity of
aPL are analyzed. Triple positivity in particular seems to
be associated with a higher risk for the appearance of
clinical APS manifestations [14]. In this context, LA
positivity seems to be the best predictor, whereas
medium/high levels of IgG to CL and β2GPI are more
indicative than low levels thereof and IgM, although it
has recently been suggested that the IgM isotype also
has predictive value [14, 15].
There is growing evidence that aPL are pathogenic,
although aPL alone are not sufficient to induce APS, and
probably perpetuate APS. A “second hit” is required to
support these pathophysiological processes [16]. Factors
such as traditional cardiovascular risks (e.g., hyperten-
sion, diabetes mellitus, and obesity), acquired thrombotic
risks (e.g., smoking, oral contraception, and pregnancy),
genetic factors in hypercoagulation (e.g., factor V Leiden
or II mutation, deficiency of ATIII, and protein C and S),
and probably most important infections can provide the
required triggers for a second hit. It is still unknown
whether the persistent presence of aPL in asymptomatic
carriers means that they have not yet met the right second
hit or whether their aPL do not display pathogenic
activity. Up to date, however, current techniques included
in the classification criteria have not allowed differenti-
ation of aPL in patients with APS and those in asymptom-
atic aPL-positive (+) carriers.
Novel assay techniques have been proposed for aPL
testing, such as chemiluminescence-based methods or
fluorescence enzyme immunoassays. Recently, a new
technique employing a hydrophobic solid phase for the
simultaneous detection of different aPL has been devel-
oped [13, 17–20]. Remarkably, aPL detected by such line
immunoassays (LIAs) appear to be more closely associ-
ated with the APS phenotype than those detected by
enzyme-linked immunosorbent assay (ELISA) [18, 21].
We speculated on whether LIAs demonstrating im-
proved performance characteristics in comparison with
ELISA can be the first test able to detect aPL assisting in
the differentiation of patients with APS from asymptom-
atic aPL+ carriers and aPL-positive patients with infec-
tious diseases.
Methods
Patients and controls
In total, 207 individuals were enrolled into the study,
comprising 61 patients with APS diagnosed in accord-
ance with the international APS classification criteria
and 146 controls (Table 1). Patients with APS were
further classified as having primary APS (PAPS) with
arterial and/or venous thrombosis in the absence of any
other related disease, obstetric APS (OAPS) with
pregnancy-related complications listed in the classifica-
tion criteria (early pregnancy loss, intrauterine death,
premature birth, pre/eclampsia, and intrauterine growth
retardation), and secondary APS (SAPS) in which the
syndrome occurs alongside another autoimmune disease
[2]. Further, we included 24 aPL+ individuals with no
clinical APS manifestations during at least 3 years of fol-
low up (aPL+ asymptomatic carriers). As disease con-
trols we included 73 patients suffering from infectious
diseases (infectious diseases controls (IDC)): 3 of these
patients were infected with Epstein-Barr virus, 14 with
Toxoplasma gondii, 24 with cytomegalovirus (CMV), 8
with Rubella virus, 1 with hepatitis C and 23 with Trepo-
nema pallidum displaying a positive Venereal Disease
Research Laboratory test result (VDRL+)). All the pa-
tients were attending the outpatient clinic at the
Division of Rheumatology of the University of Milan.
The study was approved by the local ethical commit-
tee (Comitato Etico Milano Area B; 08.07.2014, CS-
GA-115565) and complies with the World Medical
Association Declaration of Helsinki on the ethical
conduct of research involving human subjects and/or
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animals. Written informed consent was obtained from
each patient. All sera had been stored at –20 °C.
Sera with APS characterized for reactivity against do-
main 1 (D1) or domains 4/5 (D4/5) were also included.
The domain specificity was carried out by solid-phase
assays as previously described [22]. In detail, five pa-
tients with APS, who were negative for anti-D1 and
positive for anti-D4/5 antibodies, and 9 patients with
APS who were positive for anti-D1 and negative for
anti-D4/5 antibodies, were analyzed for their reactivity
by LIA. The clinical and laboratory features of these pa-
tients are reported in Additional file 1: Table S1.
Monoclonal and polyclonal antibodies against PL-binding
proteins
To investigate the interaction with β2GPI in the novel
assay environment, we employed the chimeric human
monoclonal IgG (humoAb) HCAL, composed of human
k and γ constant regions and variable regions from the
mouse monoclonal β2GPI‐dependent anti-CL antibody
(aCL) WBCAL‐1 [23]. The humoAb HCAL was from
Inova Diagnostics (San Diego, CA, USA). To determine
β2GPI domain reactivity we tested MBB2 - a human
minibody containing a single chain fragment variable
fused to an IgG1 CH2-CH3-domain that recognizes D1
of human ß2GPI [24]. The humoAb RR7F interacting
with PL in the ELISA was used to analyze the reactivity
to PL immobilized on the hydrophobic membrane
employed in LIA [25].
An anti-PT (aPT) moAb (Kerafast, Boston, USA) and
an anti-AnV (aAnV) (Cusabio, Wuhan, China) poly-
clonal antibody were employed to investigate the binding
to PT and AnV. To reveal their specific binding, poly-
clonal anti-mouse and anti-rabbit IgG labeled with per-
oxidase were used as secondary antibodies, respectively.
Interaction of PL-binding proteins with PL
The PL-binding proteins, human β2GPI purified from
pooled plasma as described elsewhere [26], purified hu-
man PT (Arotec Diagnostics, Wellington, New Zeeland),
and recombinant human AnV (Diarect, Freiburg,
Germany) were used. These PL-binding proteins were
investigated for their binding to PL immobilized on the
LIA membrane. Ultrapure Bovine Serum Albumin (BSA;
Sigma, St Louis, MI, USA), which was free of any β2GPI
contamination was used in some experiments.
Inhibition of aPL reactivity by CL micelles
For aPL inhibition experiments, CL micelles prepared in
a suspension as described elsewhere were employed [27].
Briefly, aß2GPI and aPL humoAbs at a dilution giving
positive results in the LIA (1.5 times the cutoff of 50 op-
tical density units) were incubated with 10 mg/L CL
micelles in PBS for 1 h at 37 °C on a rotator and subse-
quently overnight at 4 °C. After ultracentrifugation at
16,000 rpm for 45 minutes, the supernatant was col-
lected and the remaining aß2GPI and aPL reactivity de-
termined in the LIA.
Table 1 Characteristics of 61 patients with antiphospholipid syndrome and 146 controls enrolled in the study
Number Median age, years Age range, years Gender f/m
PAPS* 34 46 21–75 23/11
arterial thrombosis 23 47 21–66 15/8
venous thrombosis 12 42 28–63 8/4
thrombotic and obstetric manifestations 5 41 33–51 5/0
OAPSa 22 39 27–62 22/0
early pregnancy loss (<10th week of gestation) 11 38 34–45 11/0
intrauterine death (>10th week of gestation) 14 40 27–57 14/0
premature birth 5 37 33–42 5/0
fetuses with intrauterine growth retardation 9 35 27–42 9/0
pre/eclampsia 6 34 27–37 6/0
SAPSb 5 38 24–58 4/1
aPL+ 24 42 22–71 22/2
IDC 50 35 6–86 46/4
VDRL+ 23 36 19–58 2/21
HS 49 37 19–68 9/40
PAPS primary antiphospholipid syndrome, OAPS obstetric primary antiphospholipid syndrome, HS healthy subjects, aPL+, anti-phospholipid antibody positive, IDC
infectious diseases controls, VDRL+ Venereal Disease Research Laboratory test positive, f female, m male. aPatients with PAPS or OAPS may have more than one of
the indicated clinical manifestations. bSecondary antiphospholipid syndrome (SAPS): three were associated with systemic lupus erythematosus, two out of three
with arterial thrombosis and one with arterial thrombosis and intrauterine death; two were associated with undifferentiated connective tissue disease and with
intrauterine deaths
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ELISA for the detection of aCL and aß2GPI
For the detection of aCL and aß2GPI in patient sera,
commercially available solid-phase ELISAs employing
purified human ß2GPI in complex with CL and human
ß2GPI were used, respectively (GA Generic Assays
GmbH, Dahlewitz, Germany). Sera were considered
positive when their concentration exceeded the cutoff of
10 U/mL for IgG and IgM, respectively. All samples have
been tested by respective in-house assays as described
elsewhere [22]. The results for the two techniques were
comparable (data not shown).
LIA for the detection of aPL
Antibodies against CL, phosphatidic acid (aPA), phos-
phatidylcholine (aPC), phosphatidylethanolamine (aPE),
phosphatidylglycerol (aPG), phosphatidylinositol (aPI),
PS (aPS) and the PL-binding proteins ß2GPI, AnV,
and PT were detected in patient sera simultaneously
using a commercially available LIA in accordance
with the recommendations of the manufacturer (GA)
[17]. Briefly, CL, PA, PC, PE, PG, PI, PS, and ß2GPI,
AnV and PT were sprayed onto a polyvinylidene difluoride
(PVDF) membrane in lines for immobilization as de-
scribed for glycolipids [28]. A mixture of human IgG and
IgM was immobilized likewise as the reaction control
band.
Serum samples were diluted 1 in 33 (30 μL + 1 mL)
and incubated for 30 minutes at room temperature while
shaking to allow sufficient binding of autoantibodies to
the PL and proteins immobilized on the PVDF mem-
brane. Unbound serum components were removed by
the following wash step with 1 mL wash buffer contain-
ing 10 mM TRIS with 0.1 % Tween 20 for 5 minutes. In
a further incubation step of 15 minutes at room
temperature, the bound autoantibodies reacted specific-
ally with anti-human IgG or IgM conjugated to horse-
radish peroxidase (POD). Excessive conjugate was
separated from the solid-phase immune complexes by
an additional wash step. After addition of 50 μL precipi-
tating tetramethylbenzidine as substrate for staining,
stripes were dried for at least 30 minutes at room
temperature.
Processed strips were analyzed densitometrically
employing a scanner with the evaluation software Dr.
DotLine Analyzer (GA Generic Assays). Optical density
values equaling or above 50 were scored positive. This
cutoff was determined by calculating the 99 % percentile
of 150 apparently healthy individuals as recommended
by the international classification criteria for aPL testing
and Clinical and Laboratory Standards Institute (CLSI)
guideline C28-A3 [2, 29]. Linearity of dilution with op-
tical density values was demonstrated in the range from
10 to 80 optical density units for most of the aPL-
positive samples.
LA testing
Analysis of LA was performed in accordance with the
international recommendations as described recently
[30]. LA activity was evaluated in citrated plasma using
the ACL TOP coagulation system (Instrumentation
Laboratory SpA, Milan, Italy) by the HemosIL™ Silica
Clotting Time (SCT) and diluted Russell’s Viper Venon
(dRVVT) screen/confirm assays, together with dRVVT
and APTT mixing test, according to manufacturer’s
protocol and the international guidelines for LA meas-
urement [30].
Statistical analysis and determination of assay
performance characteristics
Fisher’s exact test with two-tailed probability was used
to test the differences between groups. Inter-rater agree-
ment statistics were applied for comparison of classifica-
tions. Rank correlation of variables was performed by
Spearman’s correlation analysis. Medcalc statistical soft-
ware (Medcalc, Mariakerke, Belgium) was used for all
statistical calculations. P values <0.05 were considered
significant.
Results
Reactivity patterns of monoclonal aPL to PL-binding
proteins in the LIA
To analyze the reactivity to PL-binding proteins
employed in the LIA, aß2GPI humoAbs MBB2 and
HCAL or monoclonal aPT or polyclonal aAnV were
tested: (1) alone, (2) with the addition of the respective
antigens, (3) with the addition of ultra-pure BSA as a
control protein, and (4) with the addition of normal hu-
man serum as a source of the PL-binding proteins. As
expected, MBB2 and HCAL humoAbs alone reacted
only with immobilized ß2GPI on the LIA membrane
(Fig. 1). Likewise, monoclonal aPT and polyclonal aAnV
also bound specifically to their corresponding immobi-
lized antigens (Fig. 2).
Co-incubation of the aß2GPI humoAbs with serum re-
vealed additional positive bands, indicating reactivity
with immobilized CL, PA, PS, and to a lesser extent with
PG and PI. In contrast, such additional bands were not
detected for the simultaneous incubation of serum with
the polyclonal aPT and aAnV (Fig. 2). The additional
bands detected for the aß2GPI humoAb incubation with
serum could be reproduced by incubating the immobi-
lized PL on the strips either prior to or simultaneously
with purified ß2GPI (Fig. 1). ß2GPI interacted with the
immobilized negatively charged CL, PA, PS, PG and PI
in a dose-dependent manner and was subsequently rec-
ognized by the aß2GPI humoAbs (data not shown).
Thus, the lower reactivity of the HCAL when incubated
with serum is probably due to the lower final concentra-
tion of ß2GPI in the diluted serum.
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Fig. 1 Reactivity of human monoclonal anti-beta2 glycoprotein I (aß2GPI) antibodies MBB2 (a) and HCAL (b) with phospholipids (PL) and PL-binding
proteins by line immunoassay (LIA): MBB2 (0.1 mg/L) and HCAL (0.02 mg/L) were run in the LIA alone or together with serum, ß2GPI, blood donor
serum, and bovine serum albumin (BSA). As the positive reaction control a mixture of human IgG and IgM was immobilized. a 1, 0.1 mg/L aß2GPI
MBB2; 2, 0.1 mg/L aß2GPI MBB2 + 10 mg/L ß2GPI; 3, 0.1 mg/L aß2GPI MBB2 + 10 mg/L BSA; 4, 0.1 mg/L aß2GPI MBB2 + 30 μL serum (1/33); and 5,
30 μL serum (1/33). b 1, 0.02 mg/L aß2GPI HCAL; 2, 0.02 mg/L aß2GPI HCAL + 10 mg/L ß2GPI; 3, 0.02 mg/L aß2GPI HCAL + 10 mg/L BSA; 4, 0.02 mg/L
aß2GPI HCAL + 30 μL serum (1/33); and 5, 30 μL serum (1/33)
Fig. 2 Reactivity of anti-prothrombin (aPT) mouse monoclonal (a) and anti-annexin V (aAnV) rabbit polyclonal antibodies (b) with phospholipids (PL)
and PL-binding proteins by line immunoassay (LIA): aPT and aAnV were run in the LIA alone or together with blood donor serum, bovine serum
albumin (BSA) and PT and AnV, respectively. As the positive reaction control a mixture of human IgG and IgM was immobilized. The control band was
only revealed when anti-human IgG coupled to horseradish peroxidase was used as secondary antibody conjugate. a 1, 1.0 mg/L aPT; 2, 1.0 mg/L
aPT + 10 mg/L PT; 3, 1.0 mg/L aPT + 10 mg/L BSA; 4, 1.0 mg/L aPT + 30 μL serum (1/33); and 5, 30 μL serum (1/33). b 1, 5.0 mg/L aAnV; 2, 5.0 mg/L
aAnV + 10 mg/L AnV; and 3, 5.0 mg/L aAnV + 10 mg/L BSA
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In contrast, incubation of PT with the LIA strips
followed by aPT mAb and of AnV followed by poly-
clonal aAnV did not reveal additional bands, indicating
no binding of PT and AnV with the immobilized PL
(Fig. 2). High Ca2+ ion concentration is known to favor
the immunogenic conformational change of PT in solid
phase assays [13]; however, the addition of Ca2+ ions up
to a concentration of 20 mM/L did not affect this re-
activity pattern.
The human monoclonal aPL RR7F (IgG) known to
be reactive with several PL in a manner completely
independent of PL-binding proteins [25] was employed
to investigate the reactivity with PL on LIA strips
(Fig. 3). It showed reactivity with CL, PA, and PS only.
Co-incubation of ß2GPI did not interfere with such a
reactivity pattern, whereas serum co-incubation re-
vealed less staining of all bands, probably due to
unspecific blocking by serum components (Fig. 3).
Interestingly, the reactivity of RR7F to PL was com-
pletely blocked by 10 mg/L CL micelles (Fig. 4). In
contrast, the aß2GPI reactivity of MBB2 and HCAL
was not affected by co-incubation with CL micelles
(Fig. 4).
Comparison of aPL testing by LIA and ELISA
To detect aPL profiles and to analyze possible differ-
ences in aPL detection, we tested sera from APS pa-
tients and controls by classical ELISA and novel LIA.
Comparison of the LIA technique with the aPL assays
recommended by the international classification cri-
teria revealed good agreement for IgG/IgM aß2GPI
and aCL (Cohen’s kappa = 0.78, 95 % CI 0.64, 0.88
and 0.72, 95 % CI 0.62, 0.82, respectively). On the other
hand, comparing the study cohorts, the only significant
Fig. 3 Reactivity of antiphospholipid (aPL) human monoclonal antibody RR7F with PL and PL-binding proteins by line immunoassay (LIA): RR7F
(10.0 mg/L) was run in the LIA alone or together with serum, beta2 glycoprotein I (aß2GPI), blood donor serum, and bovine serum albumin (BSA).
As positive reaction control a mixture of human IgG and IgM was immobilized. 1, 10.0 mg/L RR7F; 2, 10.0 mg/L RR7F + 10 mg/L ß2GPI; 3, 10.0 mg/L
RR7F + 10 mg/L BSA; 4, 10.0 mg/L RR7F + 30 μL serum (1/33); and 5, 30 μL serum (1/33)
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difference was for IgG aCL detected by LIA versus ELISA
in asymptomatic aPL+ carriers (McNemar’s test, 29.17 %,
95 % CI 5.27, 29.17, p = 0.0156). In contrast, IgM aCL
did not demonstrate a significant difference by either
method in this group (12.00 %, 95 % CI –8.66, 19.8,
p = 0.3750). This finding was due to the significantly
higher prevalence of IgG/M aCL positive samples de-
tected by ELISA compared with LIA in this group
(17/24 vs. 9/24, p = 0.0415).
Comparing the distinct isotypes of the recommended
aPL detected by LIA and ELISA in 161 patients with
APS and 156 controls, there was good agreement for
aCL and aß2GPI IgG (Cohen’s kappa = 0.75 and 0.78, re-
spectively) as well as for aCL and aß2GPI IgM (Cohen’s
kappa = 0.64 and 0.65, respectively; Additional file 2:
Table S2). On quantitative analysis of aCL IgG and IgM,
and aß2GPI IgG and IgM, by LIA and ELISA there was
significant correlation, with Spearman correlation coeffi-
cients (ρ) ranging from 0.566 to 0.774, respectively
(p < 0.001), (Fig. 5).
Comparison of aPL testing in APS patients and controls
As expected, patients suffering from APS (n = 61) had sig-
nificantly higher prevalence of IgG/IgM aCL and aß2GPI
detected by ELISA compared with those in IDC and HS
(Table 2). However, comparing APS with VDRL+ patients,
only IgG/IgM aß2GPI were significantly more prevalent in
patients with APS (Fig. 6). In contrast, in asymptomatic
aPL+ carriers the prevalence of all aPL detected by ELISA
was not significantly different compared with patients suf-
fering from full-blown APS (Fig. 6).
As a matter of fact, IgG/IgM reactivity against CL and
ß2GPI by LIA was significantly higher in APS samples
vs. HS and IDC groups as detected by ELISA. Of note,
IgG binding to CL and ß2GPI in the LIA was signifi-
cantly lower in aPL+ carriers and VDRL+ samples than
in APS (Fig. 6). Sera that were positive in aCL and/or
aß2GPI ELISAs also displayed reactivity with the anionic
PL in the LIA strips. Only a minority of samples dis-
played reactivity against PT, or AnV and PE (mainly of
IgM isotype) (Table 2).
Fig. 4 Inhibition of anti-beta2 glycoprotein I (aß2GPI) human monoclonal antibodies (humoAb) MBB2 and HCAL and antiphospholipid (aPL)
humoAb RR7F by cardiolipin (CL) micelles in the line immunoassay (LIA): aß2GPI and aPL humoAb were run in the LIA alone or together with
10 mg/L CL micelles. As the positive reaction control a mixture of human IgG and IgM was immobilized. 1, 0.1 mg/L aß2GPI MBB2; 2, 0.1 mg/L
aß2GPI MBB2 + CL micelles; 3, 0.02 mg/L aß2GPI HCAL; 4, 0.02 mg/L aß2GPI HCAL + CL micelles; 5, 10.0 mg/L aPL RR7F; and 6, 10.0 mg/L aPL
RR7F + CL micelles
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The significant reduced prevalence of aCL and aß2GPI
IgG analyzed by LIA in aPL+ carriers compared to APS
patients were confirmed by quantitative LIA testing
(Fig. 7). The median optical density (OD) level of aCL
IgG in aPL+ carriers (0.1, 95 % CI 0.1, 43.3) was signifi-
cantly lower than in APS patients (81.0, 95 % CI 65.8,
101.6, p = 0.0005). Likewise, the median OD level of
aß2GPI IgG in aPL+ carriers (0.1, 95 % CI 0.1, 48.0) was
significantly reduced in contrast to the one in APS pa-
tients (65.0, 95 % CI 46.8, 93.2, p = 0.0066). Such signifi-
cant differences were not observed by quantitative aCL
and aß2GPI IgG ELISA analysis (p > 0.05, respectively)
(Fig. 7).
In order to investigate the reasons for significant dif-
ferences on qualitative and quantitative LIA testing of
APS patients and controls, we tested nine patients with
APS and aPL IgG reactivity to D1 of ß2GPI only and five
with aPL reactivity to D4/5 only. Domain reactivity was
determined by research assays as described in “Methods”.
Remarkably, nine of nine patients with APS and sole D1
reactivity scored positive in the LIA, whereas, in contrast
none of the five patients with APS and D4/5 reactivity
were positive (Table 3) (p = 0.0005).
Notably, LA analysis, like ELISA testing, did not reveal
significant differences in the prevalence of aPL when
comparing patients with APS to asymptomatic aPL+ car-
riers. Altogether, only aPL IgG analysis by LIA discrimi-
nated APS patients from aPL+ carriers.
In this study, evaluating at least one positive assay, the
multiplex LIA demonstrated sensitivity of 86.9 %
compared to 75.4 % by single ELISAs and 85.2 % by LA
analysis. By employing different disease controls, the
specificity reached similar values of 74 % for ELISA and
72 % for LIA testing when excluding aAnV IgM, which
was positive in all patients with CMV infection (n = 10).
Sensitivity of 67.2 % by LIA vs. 58.8 % by ELISA at a
higher specificity of around 95 % for both techniques
has been reported in an earlier study (Table 4).
Comparison of aPL testing in APS patient subgroups
Comparing patients suffering from PAPS/T and OAPS,
there was significantly higher prevalence of aCL deter-
mined by ELISA in patients with PAPS/T (27/29 vs. 11/
22, p = 0.0001). Further, the prevalence of at least one
aPL positivity detected by ELISA (aß2GPI IgG/IgM and/
or aCL IgG/IgM positive) was also significantly higher in
PAPS/T patients compared to those with OAPS (27/29
vs. 12/22, p = 0.0021). aCL and aPS IgG were also signifi-
cantly more prevalent in patients with PAPS/T compared
to those with OAPS (p = 0.04973 and p = 0.01154,
Fig. 5 Spearman’s rank correlation analysis of anti-cardiolipin (aCL) IgG (a), aCL IgM (b), anti-beta 2 glycoprotein I (aß2GPI) IgG (c), and aß2GPI
IgM (d) quantitative testing. Antiphospholipid antibodies were determined in 61 patients with antiphospholipid syndrome (APS) and 146 controls
by line immunoassay (LIA) and enzyme-linked immunosorbent assay (ELISA). The following correlation coefficients (ρ) were obtained for aCL IgG
and IgM, and aß2GPI IgG and IgM quantitative testing by LIA and ELISA (aCL IgG: ρ = 0.737 95 % CI 0.657, 0.801; aCL IgM: ρ = 0.593 95 % CI 0.482,
0.686; aß2GPI IgG: ρ = 0.774 95 % CI 0.702, 0.830; aß2GPI IgM: ρ = 0.566 95 % CI 0.449, 0.663, respectively; p < 0.001). aPL+ asymptomatic patients
with autoantibodies to phospholipids, IDC infectious diseases controls, OAPS obstetric antiphospholipid syndrome, PAPS primary antiphospholipid
syndrome, SAPS secondary antiphospholipid syndrome, VDRL+ Venereal Disease Research Laboratory test positive, OD optical density
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respectively) in the LIA test. Of note, there was no sig-
nificant difference in the prevalence of aPL when com-
paring patients with PAPS/T and OAPS in analysis of
LA.
Discussion
The persistent presence of aPL is the serological hallmark
of APS and represents one of its mandatory classification
criteria [2]. It is a well-accepted consensus that aPL inter-
act with PL-binding proteins. While most of the reactivity
was against β2GPI, additional PL-binding proteins were
shown to be recognized by aPL [11–13, 16]. The different
aPL subpopulations cannot be detected by a single diag-
nostic assay and this supports the recommendation for
performing aCL, aβ2GPI, and LA assays in order to iden-
tify all the potential aPL.
Between 1 % and 5 % of healthy individuals have circu-
lating aPL that are detectable with the currently recom-
mended aPL assays [4]. This raises the issue of
identifying the truly diagnostic aPL and/or those aPL
that are really predictive for the clinical manifestations
of the syndrome.
The LIA membrane strips provide a unique matrix
that allows PL to mimic their natural conformation in
tissues as reported for other amphiphatic non-protein
antigenic molecules [28, 31–33]. Hence, immobilized PL
offer a suitable binding substrate for the main PL-
binding proteins. Accordingly, this study investigated the
performance of a novel LIA hydrophobic solid phase for
the simultaneous detection of multiple aPL in a well-
defined cohort of patients with APS and controls includ-
ing aPL+ asymptomatic carriers.
Of note, the novel LIA solid phase has already proven
its usefulness for the specific analysis of auto-antibodies
to lipopolysaccharides and glycolipids exhibiting PL-like
physicochemical characteristics [28, 33]. In contrast to
the planar ELISA solid phase, the porous hydrophobic
LIA membrane is assumed to incorporate the hydropho-
bic PL tail. This shields the by far larger tail of the
amphiphatic PL molecule from the reaction environ-
ment and, thus, prevents unspecific interactions [11]. Of
note, the humoAb RR-7 F interacting with anionic PL
only in ELISA also bound readily immobilized anionic
PL in the investigated LIA [25]. This reactivity was
Table 2 Antiphospholipid antibody (aPL) positive sera tested by enzyme-linked immunosorbent immunoassay (ELISA) and line im-
munoassay (LIA) in 61 patients with antiphospholipid syndrome (APS) and 146 controls
ELISA LIA LA
aCL aß2GPI Any aPL aCL aPA aPC aPE aPG aPI aPS aAnV aß2GPI aPT any aPL
G M G M G/M G M G M G M G M G M G M G M G M G M G M G/M
APS
n = 61
45 31 31 29 46 45 26 31 25 0 0 0 11 18 12 25 16 43 28 3 4 38 29 8 11 53 52
PAPS
n = 34
31 21 21 20 31 29 18 20 18 0 0 0 7 13 10 17 11 29 20 1 3 25 19 6 6 31 29
PAPS/T
n = 29
27 18 17 17 27 25 15 17 15 0 0 0 4 11 9 13 10 25 17 1 2 21 16 5 4 26 24
PAPS/TO
n = 5
4 3 4 3 4 4 3 3 3 0 0 0 3 2 1 4 1 4 3 0 1 4 3 1 2 5 5
OAPS
n = 22
11§ 8 8 8 12§ 13§ 7 8 6 0 0 0 4 4 2 7 4 11§ 7 2 1 10 8 1 4 18 19
SAPS
n = 5
3 2 2 1 3 3 1 3 1 0 0 0 0 1 0 1 1 3 1 0 0 3 2 1 1 4 4
aPL +
n = 24
13 9 7 6 17 6** 6 6*** 6 0 0 0 0* 3 1 4* 3 5** 6 0 2 8* 10 1 1 17 20
IDC
n = 50
3** 1** 0** 0** 4** 0** 0** 0** 0** 0 0 0 0* 0** 0* 0** 1* 0** 0** 2 10* 0** 1** 1* 4 16** nd
VDRL +
n = 23
13 8 3* 1* 15 7* 9 0** 1* 0 0 0 1 0* 1* 0* 1* 0** 1* 1 2 0** 2* 0 5 12* nd
HS
n = 49
0** 2** 0** 0** 2** 1** 1** 1** 0** 0 0 0 4 0** 0* 1** 0** 1** 0** 0 0 0** 0** 0* 0* 6** nd
*P < 0.05 and **p < 0.0001 for comparison of prevalence of aPL in patients with APS (n = 61) and the respective control cohort; ***trend towards difference in
prevalence of aPL in patients with APS (n = 61) and the respective control cohort (p = 0.05). §P < 0.05 for comparison of prevalence of aPL in PAPS/T patients
(n = 29) with SAPS or OAPS patients. aAnV antiannexin V, aß2GPI antibeta2-glycoprotein I, aCL anticardiolipin, aPA antiphosphatidic acid, aPC antiphosphatidylcholine,
aPE antiphosphatidylethanolamine, aPG antiphosphatidylglycerol, aPI antiphosphatidylinositol, aPL+ asymptomatic patients with autoantibodies to phospholipids,
aPS antiphosphatidylserine, aPT antiprothrombin, HS healthy subjects, IDC infectious diseases controls, LA lupus anticoagulant, nd not determined, OAPS obstetric
primary antiphospholipid syndrome, PAPS primary antiphospholipid syndrome, PAPST primary antiphospholipid syndrome with thrombotic events, PAPS/TO
primary antiphospholipid syndrome with thrombotic and obstetric manifestations, SAPS secondary antiphospholipid syndrome, VDRL+ Venereal Disease Research
Laboratory test-positive
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completely inhibited by CL micelles that expose only
hydrophilic CL-heads on their surface in aqueous solu-
tions. Consequently, this confirms the interaction of RR-
7 F with the hydrophilic PL-heads on the PVDF mem-
brane. The aβ2GPI humoAbs MBB2 and HCAL were
able to recognize their target molecule coated on the
membrane as well as to react with anionic PL through
the bound cationic β2GPI.
Interestingly, the addition of serum or purified β2GPI
to MBB2 revealed different binding characteristics to the
immobilized anionic PL in the novel reaction environ-
ment. CL, also referred to as diphosphatidylglycerol,
binds β2GPI far better than its monomeric variant PG.
Otherwise, PS bearing only one phosphatic group has a
better binding than PI or PG. This supports the assump-
tion that the number, orientation, and accessibility of an-
ionic phosphatic groups in the hydrophilic PL heads
determine the binding of β2GPI and consequently of the
β2GPI-dependent aPL. As MBB2 has been demonstrated
to specifically react with D1 of ß2GPI and its conform-
ational epitope [24], its binding to the LIA strips indi-
cates that the immobilized β2GPI readily exposes D1.
This demonstrates the accessibility of this important
pathogenic epitope-bearing domain in the LIA reaction
environment. As a consequence, these variables may
affect the ultimate serum autoantibody binding.
Indeed, favorable assay performance particularly for
the specificity of this novel LIA technique for the
analysis of aPL has been reported recently and was
confirmed in this study [17, 21]. In fact, the preva-
lence of aCL and aß2GPI IgG was significantly re-
duced in aPL+ carriers and in VDRL+ individuals
compared to patients with APS when analyzed by LIA
but not by ELISA. Of note, the significantly qualita-
tive differences of aCL IgG and aß2GPI IgG testing
by LIA in APS patients and aPL+ carriers were con-
firmed by quantitative analyses of the respective me-
dian OD levels.
We could not determine the binding of either serum
or purified PT with immobilized anionic PL, particularly
with PS, in the multiplex LIA environment as shown
for β2GPI. Even in the presence of Ca+2 ions, which
are required for the aPT/PS ELISA reaction environ-
ment, no binding was detected. However, it cannot be
excluded that the PT in the LIA reaction environment
is not able to change its conformation in the presence
of Ca2+ ions. This point could not be addressed by
our experimental setting. Addition of further PT in
the presence of the right high Ca++ concentration
did not change the binding behavior. Of note, there
was a significantly different prevalence of aPT and
aPS IgG/IgM (p < 0.0001 and p = 0.0017, respectively)
in APS patients by LIA. Altogether, this indicates that
aPS reactivity in LIA is mainly based on the reactivity
to β2GPI bound to PS and does not involve PT
present in the serum sample. Theoretically in fact,
Fig. 6 Prevalence of consensus criteria antiphospholipid antibodies (aPL) tested by line immunoassay (LIA), enzyme-linked immunosorbent assay
(ELISA), and lupus anticoagulant (LA) analysis in 61 patients with antiphospholipid syndrome (APS), 24 aPL-positive (aPL+) individuals, and
23 Veneral Disease Laboratory test-positive (VDRL+) patients. aß2GPI antibeta2-glycoprotein I, aCL anticardiolipin, aPA antiphosphatidic acid,
aPE antiphosphatidylethanolamine, aPG antiphosphatidylglycerol, aPI antiphosphatidylinositol, aPL+ asymptomatic carriers with autoantibodies to
phospholipids, aPS antiphosphatidylserine. *P < 0.05; **p < 0.0001; §not done
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Table 3 Line immunoassay (LIA) reactivity of antibeta2-glycoprotein I (aβ2GPI) domain 1 (D1) negative-D4/5 positive and D1
positive-D4/5 negative sera from patients (Pts) with antiphospholipid syndrome (APS)
aPL IgG reactivity by LIA (OD)
aβ2GPI reactivity profile Pt # aCL aPA aPC aPE aPG aPI aPS aAnV aβ2GPI aPT
aD1 negative-aD4/5 positive 1 0 0 0 0 0 0 0 0 20 0
2 0 0 0 0 0 0 0 0 30 0
3 0 17 0 0 0 0 0 0 0 0
4 0 0 0 0 0 0 0 0 27 0
5 0 0 0 0 0 0 0 0 34 0
aD1 positive-aD4/5 negative* 6 108 80 0 0 0 0 109 0 97 0
7 121 107 0 35 84 94 116 44 121 83
8 87 45 0 0 41 58 92 0 65 0
9 111 68 0 0 85 91 101 0 98 37
10 136 107 0 0 109 117 131 33 123 80
11 99 66 0 0 49 69 93 0 86 0
12 136 104 0 0 99 94 121 56 123 82
13 116 83 0 0 100 106 126 0 118 33
14 135 121 0 0 91 106 121 0 116 50
Results of antiphospholipid (aPL) IgG are expressed as optical density (OD) values whereas OD values equaling or above 50 were scored positive (positive values
in italics). aAnV antiannexin V, aCL anticardiolipin,aPA, antiphosphatidic acid; aPC, antiphosphatidylcholine; aPE antiphosphatidylethanolamine, aPG
antiphosphatidylglycerol, aPI antiphosphatidylinositol, aPS antiphosphatidylserine, aPT antiprothrombin. *P = 0.0005 vs aD1 negative-aD4/5 positive
Fig. 7 Comparison of quantitative anti-cardiolipin (aCL) IgG (a) and anti-beta 2 glycoprotein I (aß2GPI) IgG (b) analysis by line immunoassay (LIA)
and enzyme-linked immunosorbent assay (ELISA) (c, d, respectively) in patients with antiphospholipid syndrome (APS) (n = 61) and antiphospholipid
antibody-positive carriers (aPL+) (n = 24). In the box and whisker plots, outlier values are defined as values that are lower than the lower
quartile minus three times the interquartile range, or higher than the upper quartile plus three times the interquartile range, displayed as
triangles. *P = 0.0005; **p = 0.0066
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serum PT could bind PS on the PVDF membrane.
Accordingly, in our study there was no significant
correlation between thrombotic events and either aPT
or aPS detected by LIA, which was reported for aPS/
PT elsewhere [12]. The latter findings is in line with
the hypothesis that aPS/PT abs recognize a peculiar
epitope(s) exposed on PT only when complexed with
PS-coated polystyrene plates.
A further novelty of this aPL assay is the possibility
of detecting antibodies against D1 because of the way
the molecule is oriented on the matrix [34, 35]. After
binding of β2GPI to negatively charged surfaces like
immobilized anionic PL by D5 (containing the PL-
binding site), D1 forms the top of the induced
fishhook-like β2GPI structure that is predisposed to
interact with aPL [35]. Assuming a high density of
the hydrophilic PL heads on the LIA membrane,
β2GPI D4 and D5 could be indeed engaged in the
binding of immobilized PL and no longer available
for aPL interaction. Indeed, none out of five patients
with APS with D4/D5 reactivity only, had a positive
aPL IgG by LIA, whereas all nine patients with D1
reactivity only did have positive aPL by LIA. aPL di-
rected against D1 are significantly more present in
sera in APS than in pathological controls such as in-
fectious patients or aPL+ asymptomatic carriers. On
the other hand, aPL reacting with β2GPI D4 and D5
display opposite behavior [36, 37]. Indeed, there is a
significant difference in the analysis of aPL binding to
anionic PL/β2GPI complexes in LIA compared with
ELISA in VDRL+ patients and in particular in asymp-
tomatic aPL+ carriers. Thus, the significantly lower
prevalence of aPL detected by LIA in aPL+ carriers
and in VDRL+ patients indicates more specific detec-
tion of diagnostic aPL by LIA. Remarkably, on aPL
analysis by LA testing and ELISA there were no such
significant differences, which suggests the detection of
aPL to epitopes other than those present on D1. As
the aPL reactivity to D4-5 has been reported not to
be associated with thromboembolism, our data further
support the suggestion that LIA may detect aPL that
are more predictive of clinical events in APS [36–38].
Conclusions
This is the first study reporting on a diagnostic assay for
discrimination of patients with APS from asymptomatic
aPL carriers and patients with infectious diseases. The
varying aPL reactivity detected in LIA could be ex-
plained by conformational differences in the fishhook-
like structure of β2GPI interacting with PL heads homo-
genously oriented on the membrane.
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